| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA1602773 |
| P698 | PubMed publication ID | 27959607 |
| P50 | author | Bruce E. Sands | Q29922058 |
| Séverine Vermeire | Q30247983 | ||
| Stephan R. Targan | Q106967049 | ||
| Bruce A Salzberg | Q114404671 | ||
| Yinghua Lang | Q114404704 | ||
| Christopher Gasink | Q114416431 | ||
| Douglas Jacobstein | Q114422931 | ||
| Levinus A Dieleman | Q114430295 | ||
| Paul Rutgeerts | Q30247987 | ||
| Jean-Frédéric Colombel | Q30248037 | ||
| Jürgen Stein | Q54877814 | ||
| Edward V Loftus | Q56065843 | ||
| Pierre Desreumaux | Q56979864 | ||
| Seymour Katz | Q57113097 | ||
| William Jeffery Sandborn | Q64364605 | ||
| Brian G. Feagan | Q64364618 | ||
| Joshua R Friedman | Q87329933 | ||
| Stephen B Hanauer | Q87669570 | ||
| Ursula Seidler | Q89296657 | ||
| Omoniyi J Adedokun | Q100759058 | ||
| P2093 | author name string | Zsolt Tulassay | |
| Subrata Ghosh | |||
| Ye Miao | |||
| Jewel Johanns | |||
| Long-Long Gao | |||
| Marion A. Blank | |||
| Scott D. Lee | |||
| Willem J. de Villiers | |||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1946-1960 | |
| P577 | publication date | 2016-11-17 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease | |
| P478 | volume | 375 |
| Q90619145 | 2019 Expert opinion on biological treatment use in inflammatory bowel disease management |
| Q57471150 | A Practical Guide to the Safety and Monitoring of New IBD Therapies |
| Q64883615 | A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. |
| Q93177027 | A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD |
| Q48288463 | A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease. |
| Q93355924 | A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases |
| Q41129532 | A role for oncostatin M in inflammatory bowel disease |
| Q38749257 | A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases |
| Q46506676 | A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis |
| Q88249578 | ACG Clinical Guideline: Management of Crohn's Disease in Adults |
| Q57098797 | Abnormal Small Intestinal Epithelial Microvilli in Patients With Crohn's Disease |
| Q47287228 | Advances in mesenchymal stromal cell therapy in the management of Crohn's disease. |
| Q38681918 | Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects |
| Q57100580 | AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation |
| Q57471139 | An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-sectional Study |
| Q50110700 | An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients |
| Q92214071 | Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature |
| Q36203845 | Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. |
| Q41660377 | Anti-NKG2D mAb: A New Treatment for Crohn's Disease? |
| Q64075128 | Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses |
| Q94337008 | Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease |
| Q55424996 | Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin |
| Q91949578 | Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study |
| Q93106999 | Bedside to bench: defining the immunopathogenesis of psoriatic arthritis |
| Q57245356 | Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis |
| Q98164815 | Biologics and surgical outcomes in Crohn's disease: is there a direct relationship? |
| Q92440963 | Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-6 |
| Q90339285 | British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults |
| Q64902536 | Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease. |
| Q59337401 | Burden and outcomes for complex perianal fistulas in Crohn's disease: Systematic review |
| Q91789183 | Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease |
| Q91789190 | Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease |
| Q36407822 | Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease |
| Q47304240 | Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract |
| Q52364937 | Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. |
| Q90656651 | Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis |
| Q49218809 | Clinical utility of ustekinumab in Crohn's disease. |
| Q48172992 | Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort |
| Q33646452 | Combination therapy for inflammatory bowel disease |
| Q52581473 | Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. |
| Q58803120 | Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden |
| Q92024709 | Covid-19 and immunomodulation in IBD |
| Q39122303 | Crohn's disease for the general physician: management |
| Q92325235 | Crohn's disease is facilitated by a disturbance of programmed death-1 ligand 2 on blood dendritic cells |
| Q99929804 | Crohn’s disease |
| Q38763559 | Current and emerging therapeutic targets for IBD. |
| Q52664758 | Cytokines in uveitis. |
| Q60050768 | Dendritic cell profiles in the inflamed colonic mucosa predict the responses to tumor necrosis factor alpha inhibitors in inflammatory bowel disease |
| Q64247111 | Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease |
| Q46027208 | Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. |
| Q90251473 | Development of gut-selective pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: A translational medicine program |
| Q38750042 | Developments in therapy with monoclonal antibodies and related proteins. |
| Q90303557 | Differences in Peripheral and Tissue Immune Cell Populations Following Haematopoietic Stem Cell Transplantation in Crohn's Disease Patients |
| Q92447462 | Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD |
| Q90049795 | Drug Lag for Inflammatory Bowel Disease Treatments in the East and West |
| Q50020853 | Drug development in the era of precision medicine. |
| Q90055639 | Early real-world effectiveness of ustekinumab for Crohn's disease |
| Q48267364 | Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience |
| Q89209037 | Effect of a concomitant elemental diet with maintenance anti-tumor necrosis factor-α antibody therapy in patients with Crohn's disease: A multicenter, prospective cohort study |
| Q91974577 | Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses |
| Q89978216 | Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review |
| Q47121808 | Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies |
| Q38702997 | Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis |
| Q92759074 | Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape |
| Q58099968 | Emerging Therapies for Inflammatory Bowel Disease |
| Q89793251 | Emerging treatments for inflammatory bowel disease |
| Q92351038 | Engineered Lactococcus lactis Secreting IL-23 Receptor-Targeted REX Protein Blockers for Modulation of IL-23/Th17-Mediated Inflammation |
| Q38741014 | Enrichment of IL-17A+ IFN-γ+ and IL-22+ IFN-γ+ T cell subsets is associated with reduction of NKp44+ ILC3s in the terminal ileum of Crohn's disease patients. |
| Q92358318 | Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease |
| Q55470114 | Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn's disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose-response trial. |
| Q99632335 | Extrapolating Pharmacodynamic Effects from Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients with Moderate to Severe Plaque Psoriasis |
| Q89459590 | First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician |
| Q39424463 | Frontiers in Drug Research and Development for Inflammatory Bowel Disease |
| Q39238723 | Genetics of inflammatory bowel disease: beyond NOD2. |
| Q63352496 | Genome wide analysis for mouth ulcers identifies associations at immune regulatory loci |
| Q92551084 | Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial |
| Q90248075 | Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment |
| Q41044153 | Hair Growth in Two Alopecia Patients after Fecal Microbiota Transplant |
| Q91636298 | Human Intestinal Mononuclear Phagocytes in Health and Inflammatory Bowel Disease |
| Q99238862 | Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease |
| Q97644859 | IBD considerations in spondyloarthritis |
| Q53747203 | IBD in 2016: Biologicals and biosimilars in IBD - the road to personalized treatment. |
| Q50057718 | IBD in 2017: Development of therapy for and prediction of IBD - getting personal |
| Q88970520 | IBD: Ustekinumab therapy for Crohn's disease |
| Q92647964 | IL-10 signaling in dendritic cells controls IL-1β-mediated IFNγ secretion by human CD4+ T cells: relevance to inflammatory bowel disease |
| Q93381993 | IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting |
| Q90345257 | IL-17C/IL-17RE: Emergence of a Unique Axis in TH17 Biology |
| Q92760637 | IL-23-producing IL-10Rα-deficient gut macrophages elicit an IL-22-driven proinflammatory epithelial cell response |
| Q64066256 | ILC3 function as a double-edged sword in inflammatory bowel diseases |
| Q52804774 | Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In |
| Q64097732 | Immune regulation mechanism of vitamin D level and IL-17/IL-17R pathway in Crohn's disease |
| Q48336044 | Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response? |
| Q91592695 | Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor |
| Q30235581 | Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. |
| Q46482643 | Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study |
| Q39429997 | Infection risk with biologic therapy in patients with inflammatory bowel disease |
| Q52564079 | Inflammatory Bowel Disease and Immunonutrition: Novel Therapeutic Approaches Through Modulation of Diet and the Gut Microbiome. |
| Q94502919 | Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors |
| Q57067878 | Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease |
| Q91618743 | Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells |
| Q91452268 | Interrogating host immunity to predict treatment response in inflammatory bowel disease |
| Q64078046 | Intestinal Organoids as a Novel Complementary Model to Dissect Inflammatory Bowel Disease |
| Q92759059 | Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases |
| Q55259683 | Intraperitoneal administration of the anti-IL-23 antibody prevents the establishment of intestinal nematodes in mice. |
| Q55505680 | Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease? |
| Q47439880 | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases |
| Q48556502 | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. |
| Q38805575 | Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases |
| Q50782815 | Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. |
| Q55693561 | Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. |
| Q48282663 | Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. |
| Q90201609 | MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota |
| Q91615855 | Macrophage interactions with fungi and bacteria in inflammatory bowel disease |
| Q90397147 | Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges |
| Q33819478 | Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease |
| Q38735146 | Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities |
| Q53828883 | Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. |
| Q40054186 | Management of patients with inflammatory bowel disease and spondyloarthritis |
| Q90259417 | Maneuvering Clinical Pathways for Crohn's Disease |
| Q90320869 | Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More |
| Q57788239 | Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease |
| Q38668874 | Medical versus surgical management of penetrating Crohn's disease: the current situation and future perspectives |
| Q58096703 | Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis |
| Q60954864 | Modulating T Cell Responses via Autophagy: The Intrinsic Influence Controlling the Function of Both Antigen-Presenting Cells and T Cells |
| Q48025650 | NAD metabolism fuels human and mouse intestinal inflammation. |
| Q52670920 | New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. |
| Q64917770 | New biologics and small molecules in inflammatory bowel disease: an update. |
| Q90916358 | New therapeutic perspectives to manage refractory immune checkpoint-related toxicities |
| Q52647462 | New treatment options for inflammatory bowel diseases. |
| Q38670811 | New treatment strategies for ulcerative colitis |
| Q47141159 | Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab. |
| Q91970764 | Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor |
| Q95642187 | Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors |
| Q50146115 | Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease |
| Q99636958 | Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort |
| Q48351328 | Old and New Lymphocyte Players in Inflammatory Bowel Disease |
| Q41846031 | Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. |
| Q64103975 | One Size Does Not Fit All: The Case for Translational Medicine |
| Q47389870 | Optimization of biologic therapy in Crohn's disease |
| Q98906899 | Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? |
| Q38687407 | Optimizing pharmacologic management of inflammatory bowel disease |
| Q92666608 | Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease |
| Q91623113 | Organ Failure Due to Systemic Injury in Acute Pancreatitis |
| Q96585237 | Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study |
| Q48182579 | Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab. |
| Q38750548 | Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. |
| Q38665573 | Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders |
| Q47897160 | Pathological and therapeutic roles of innate lymphoid cells in diverse diseases |
| Q57301026 | Perianal Fistulas in Patients With Crohn's Disease, Part 1: Current Medical Management |
| Q91820745 | Personalised medicine in Crohn's disease |
| Q64262376 | Personalising medicine in inflammatory bowel disease-current and future perspectives |
| Q92722359 | Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease |
| Q38726458 | Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease |
| Q50012048 | Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease |
| Q55298477 | Pharmacological activation of epidermal growth factor receptor signaling inhibits colitis-associated cancer in mice. |
| Q46103014 | Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study |
| Q40100993 | Pneumocystis jirovecii Pneumonia in Pediatric Inflammatory Bowel Disease: A Case Report and Literature Review |
| Q57167308 | Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases |
| Q38748380 | Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice |
| Q57131331 | Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn's Disease |
| Q46989239 | Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease |
| Q51828636 | Precision Medicine in Inflammatory Bowel Diseases. |
| Q91789011 | Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study |
| Q49691610 | Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis |
| Q92063389 | Profound remission in Crohn's disease requiring no further treatment for 3-23 years: a case series |
| Q59133604 | Protein Tyrosine Phosphatases: Regulators of CD4 T Cells in Inflammatory Bowel Disease |
| Q47778724 | Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). |
| Q90381040 | Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab |
| Q39215821 | Recent advances in gut immunology. |
| Q92310083 | Recent advances in understanding and managing pediatric inflammatory bowel disease |
| Q98386269 | Recurrent granulomatous cheilitis associated with Crohn's disease successfully treated with ustekinumab: case report and literature review |
| Q90268996 | Resolution of Crohn's disease |
| Q47805665 | Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. |
| Q97530140 | Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis |
| Q62633606 | Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study |
| Q90590407 | Risankizumab: a game changer in Crohn's disease? |
| Q54961768 | Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. |
| Q92669023 | Role of innate lymphoid cells in chronic colitis during anti-IL-17A therapy |
| Q90656440 | Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study |
| Q37662498 | Second Korean guidelines for the management of Crohn's disease |
| Q38645111 | Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab |
| Q64240256 | Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases |
| Q91809503 | Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD Cohort |
| Q93043721 | Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy |
| Q91825592 | Successful treatment of refractory mechanic's hands with ustekinumab in a patient with the antisynthetase syndrome |
| Q90393278 | Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis |
| Q92277529 | Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits |
| Q46265247 | TH17 Cell and Epithelial Cell Crosstalk during Inflammatory Bowel Disease and Carcinogenesis. |
| Q90189550 | Targeted Combination Antibiotic Therapy Induces Remission in Treatment-Naïve Crohn's Disease: A Case Series |
| Q45944049 | Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. |
| Q93246335 | Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis |
| Q91706522 | Targeting Mucosal Healing in Crohn's Disease |
| Q93001372 | Targeting immune cell circuits and trafficking in inflammatory bowel disease |
| Q87840221 | Targeting interleukin 23 for Crohn's disease: finding the right drug for the right patient |
| Q39233355 | The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease |
| Q92276623 | The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease |
| Q38761961 | The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease |
| Q90262614 | The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis |
| Q89999237 | The IL-23/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies |
| Q47109861 | The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. |
| Q60017517 | The current state of the art for biological therapies and new small molecules in inflammatory bowel disease |
| Q39337496 | The dichotomous nature of T helper 17 cells |
| Q44581309 | The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients? |
| Q38648792 | The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease. |
| Q98460557 | The risk of respiratory tract infections and interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis |
| Q89450520 | The state of the art on treatment of Crohn's disease |
| Q88288521 | Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease |
| Q90246589 | Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response |
| Q92650609 | Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus |
| Q52603361 | Therapy for Crohn's Disease: a Review of Recent Developments. |
| Q96953884 | Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors |
| Q94093775 | UEG Week 2018 Poster Presentations |
| Q92443656 | Ulcerative Colitis: Current and Emerging Treatment Strategies |
| Q99349994 | Ulcerative colitis |
| Q33711741 | Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model? |
| Q39435409 | Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease |
| Q64226421 | Update in treatment of uveitic macular edema |
| Q53075985 | Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series. |
| Q92674208 | Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis |
| Q90625069 | Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease |
| Q50089635 | Ustekinumab drug levels in maternal and cord blood in a woman with Crohn's disease treated until 33 weeks gestation |
| Q92895315 | Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study |
| Q47203436 | Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| Q91828617 | Ustekinumab in psoriatic arthritis and related phenotypes |
| Q28067631 | Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy |
| Q92300916 | Ustekinumab is effective in biological refractory Crohn's disease patients-regardless of approval study selection criteria |
| Q48014899 | Ustekinumab use in Crohn's disease: a Canadian tertiary care centre experience |
| Q93184539 | Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease |
| Q39320474 | Ustekinumab: A Review in Moderate to Severe Crohn's Disease |
| Q89267486 | Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium |
| Q57293183 | Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? |
| Q90007067 | [Therapeutic regimens using monoclonal antibodies in gastroenterology] |
Search more.